Ƶ

More Positive Spravato Data; Vyvanse for Amphetamine Disorders; Psych Pioneer Dies

— News and commentary from the psychiatry world

Ƶ MedicalToday
Illustration of a brain shaped maze.

Results from the phase IIIb ESCAPE-TRD trial among patients with treatment-resistant depression showed that was superior to extended-release quetiapine (Seroquel XR) for symptom remission at week 8 and remaining relapse free up to week 32, Janssen announced.

Even before the COVID-19 pandemic started, there was a spike in emergency department visits among young people ages 5 to 19 with , according to a study from Illinois. "A lot of people have talked about mental health problems in youth during the pandemic, but it was happening before the pandemic," said study author Audrey Brewer, MD, MPH, of Northwestern University Feinberg School of Medicine. (Pediatrics)

For people with , lisdexamfetamine (Vyvanse) was the only medication linked with a significantly lower risk of hospitalization and death in a Swedish cohort. Meanwhile, benzodiazepine use was tied to significantly poorer outcomes. (JAMA Psychiatry)

was not associated with previously described increased risks of autism spectrum and attention deficit-hyperactivity disorders in children after adjusting for possible genetic confounding, a Taiwanese cohort study of over 1.5 million children showed. (JAMA Network Open)

, founder of the Phoenix House and an early pioneer of residential group therapy for drug and alcohol addiction, passed away at the age of 87 earlier this month. (New York Times)

Compared with people with no psychiatric disorders, who were infected with COVID-19 were 9% more likely to be hospitalized and 8% more likely to die. (Translational Psychiatry)

A was noted among kids ages 11 to 14 in the U.K., likely due to school transitioning. (British Journal of Developmental Psychology)

No, Canada isn't for people who refuse COVID-19 vaccinations. (AP)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.